Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa
Authors:
- Lucía González-PintoLGLucía González-Pinto
- Laura Monge-OlivaresLMLaura Monge-Olivares
- Gloria Pérez-RodríguezGPGloria Pérez-Rodríguez
- Pablo Aja-MacayaPAPablo Aja-Macaya
- Lucía Sánchez-PeñaLSLucía Sánchez-Peña
- María Antonia Gomis-FontMGMaría Antonia Gomis-Font
- Salud Rodríguez-PallaresSRSalud Rodríguez-Pallares
- Tania Blanco-MartínTBTania Blanco-Martín
- Lorena López-CereroLLLorena López-Cerero
- Alejandro BeceiroABAlejandro Beceiro
- Antonio OliverAOAntonio Oliver
Open Access
- 1 July 2026
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (7) , e0180525
Abstract
We aimed to characterize OXA-1054, a novel carbapenem-hydrolyzing class D β-lactamase (CHDL) detected in a multidrug-resistant Pseudomonas aeruginosa clinical isolate. Antimicrobial susceptibility was determined by broth microdilution, and carbapenemase activity was confirmed by hydrolysis assays. Whole-genome sequencing via Illumina and PacBio platforms enabled comprehensive analysis of the resistome and plasmid architecture. The bla OXA-1054 gene was cloned in parallel with bla OXA-48 and bla OXA-198 into the pUCP24 plasmid. β-Lactamases were produced in P. aeruginosa PAO1 for comparative evaluation of the phenotypic impact of each. OXA-48, OXA-198, and OXA-1054 β-lactamases were purified and further subjected to steady-state kinetic analysis, and 50% inhibitory activity of β-lactamase inhibitors was determined. The clinical P. aeruginosa isolate ARGA00461 showed resistance to carbapenems and most β-lactam/β-lactamase inhibitor combinations and tested positive in carbapenem hydrolysis assays. Genomic analysis revealed that the P. aeruginosa isolate ARGA00461 carried a gene coding for a previously uncharacterized CHDL, designated OXA-1054, which is closely related to the OXA-372 enzyme of environmental origin. The bla OXA-1054 gene was located in a small (≈5 kbp) non-conjugative plasmid coexisting with a conjugative IncP plasmid, which likely facilitated its mobilization. Production of OXA-1054 in P. aeruginosa PAO1 conferred a broader spectrum of β-lactam resistance than other CHDLs. Enzyme kinetics confirmed carbapenem hydrolysis with catalytic efficiency comparable to OXA-48 and revealed higher affinity for cefepime compared to OXA-48 and OXA-198. Among the inhibitors tested, only avibactam demonstrated relevant inhibitory activity. OXA-1054 mediates broad-spectrum β-lactam resistance in P. aeruginosa , including carbapenems and β-lactam/β-lactamase inhibitor combinations.Keywords
Funding Information
- Axencia Galega de Innovación (IN606A 2024/022)
- Axencia Galega de Innovación (IN606A 2025/020)
- Axencia Galega de Innovación (IN607A 2024/09)
- Axencia Galega de Innovación (IN607D 2021/12)
- Axencia Galega de Innovación (IN607D 2024/08)
- Centro de Investigación Biomédica en Red de enfermedades infecciosas (CB21/13/00055)
- Centro de Investigación Biomédica en Red de enfermedades infecciosas (CB21/13/00099)
- Instituto de Salud Carlos III (FI22/00039)
- Instituto de Salud Carlos III (CM23/00104)
- Instituto de Salud Carlos III (FI23/00074)
- Instituto de Salud Carlos III (JR21/00026)
- Instituto de Salud Carlos III (PI21/00704)
- Instituto de Salud Carlos III (PI22/01212)
- Instituto de Salud Carlos III (PI25/00116)
- Instituto de Salud Carlos III (PI24/00010)
- Instituto de Salud Carlos III (PI24/00920)
- Instituto de Salud Carlos III (JR25/00031)
This publication has 44 references indexed in Scilit:
- Quantitative study of ESBL and carbapenemase producers in wastewater treatment plants in Seville, Spain: a culture-based detection analysis of raw and treated waterWater Research, 2025
- The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistanceThe Lancet Infectious Diseases, 2025
- Emerging resistance mechanisms to newer β-lactams in Pseudomonas aeruginosaClinical Microbiology and Infection, 2025
- Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditionsInternational Journal of Antimicrobial Agents, 2024
- Characterization of a novel Tn6485h transposon carrying both blaIMP-45 and blaAFM-1 integrated into the IncP-2 plasmid in a carbapenem-resistant Pseudomonas aeruginosaJournal of Global Antimicrobial Resistance, 2023
- Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysisThe Lancet Regional Health - Europe, 2023
- Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort studyThe Lancet Microbe, 2023
- A citywide, clonal outbreak of Pseudomonas aeruginosaInternational Journal of Infectious Diseases, 2022
- Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenemsJournal of Microbiology, Immunology and Infection, 2017
- Crystal Structure of the OXA-48 β-Lactamase Reveals Mechanistic Diversity among Class D CarbapenemasesChemistry & Biology, 2009